BioCentury
ARTICLE | Company News

NICE draft recommends Xarelto in ACS patients

October 23, 2014 2:50 AM UTC

The U.K.'s NICE issued draft guidance recommending use of Xarelto rivaroxaban from Bayer AG (Xetra:BAYN) in combination with aspirin plus clopidogrel or aspirin alone to prevent blood clots in patients who have acute coronary syndrome (ACS) with elevated cardiac biomarkers.

The committee noted the bleeding risk associated with the direct Factor Xa inhibitor and recommended that clinicians assess patients' risk of bleeding before treating them with Xarelto. NICE also advised clinicians to consider carefully treatment beyond 12 months. ...